At the American Heart Association’s Scientific Sessions, E-Therapeutics plc presented preclinical data for ETX-258, a Galomic siRNA being developed for the treatment of heart failure.

Primary tumors arising in the gastrointestinal system, ovary or pancreas may spread and lead to secondary cancers such as metastatic omentum cancer.

The Wiskott-Aldrich syndrome protein (WASp) is expressed exclusively in hematopoietic cells and presents either an autoinhibited or activated conformation. EG-011 is a first-in-class activator of the autoinhibited form of WASp designed for the treatment of hematological cancers.

Interleukin-1 receptor-associated kinase 4 is critical in the modulation of inflammatory responses through Toll-like receptor and IL-1R signaling.

Aizen Therapeutics has emerged from stealth with a focus on early-stage programs powered by its novel drug discovery platform, Dax.

Voyager Therapeutics Inc. has selected a lead development candidate, VY-1706, for its tau silencing gene therapy program in Alzheimer’s disease. The company anticipates filing an IND application with the FDA and a clinical trial application (CTA) with Health Canada for VY-1706 in 2026.